Cardea Health
Cardea Health is a Canadian AI-healthtech company building a cardiology-focused data platform that structures outpatient EMR data to accelerate clinical trial patient recruitment and generate real-world evidence for pharmaceutical sponsors across North America.
- Company typePrivate
- Founded2021
- HeadquartersMississauga, Canada
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What Cardea Health does
Cardea Health Inc. is a Canadian AI-healthtech company founded in 2021 and headquartered in Mississauga, Ontario, that builds the FLOW platform, a cardiology-focused data infrastructure designed to structure longitudinal outpatient EMR data and power clinical trial pre-screening, real-world evidence (RWE) generation, and implementation science. The platform is delivered through three integrated modules: ScreenFLOW for AI-powered patient pre-screening, SearchFLOW for data analysis and cohort identification, and WorkFLOW for consolidated patient data visualization. The underlying technology combines a purpose-built multi-agent (third-generation agentic) AI architecture with NLP, OCR, and a proprietary 250+ term cardiometabolic lexicon trained on real-world clinical data, with a "Reviewer in the Loop" human-in-the-loop audit layer. Cardea reports quantified performance versus manual processes: 98.2% medication identification accuracy (vs 87.2% human), 86% complex diagnosis accuracy (vs ~70% manual), 15-second patient reviews (vs 15 minutes), a 33-day faster patient identification cycle, and a 50% reduction in pre-screening spend.
Cardea serves two primary customer segments: pharmaceutical sponsors running Phase II-IV cardiometabolic and adjacent clinical trials (named engagements include Novo Nordisk, Amgen, Sanofi, and Novartis) and outpatient clinical trial site networks across North America (Heart Health Institute in Ontario, SiteCentric, Areti Health, and clinics reachable through the QHR Technologies Accuro EMR marketplace). Therapeutic areas include ASCVD, obesity, elevated lipoprotein(a), MASH, diabetes, hypertension, heart failure, kidney disease, COPD, and several oncology indications.
The business model is enterprise SaaS-like with recurring subscription/service revenue from pharma sponsors for clinical trial pre-screening and RWE programs, plus site network engagements. Pricing is quote-based (demo-led) and not publicly disclosed. The company has raised approximately $1.325M CAD to date ($975K pre-seed in October 2022 and a $350K non-dilutive FedDev Ontario grant in January 2026), operates with 1-10 employees, and has no parent company, subsidiaries, or public listing.
Cardea Health firmographics
Firmographics- Name
- Cardea Health
- Legal name
- Cardea Health Inc.
- Website
- https://cardeahealth.io
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Cardea Health is a Canadian AI-healthtech company building a cardiology-focused data platform that structures outpatient EMR data to accelerate clinical trial patient recruitment and generate real-world evidence for pharmaceutical sponsors across North America.
- Ownership category
- akta.pro rank
Cardea Health industry classification
Industry- Product category
- Clinical Trial Technology
- NAICS
- Computing Infrastructure Providers, Data Processing, Web Hosting, and Related Services (518)
- SIC
- Services-Prepackaged Software (7372)
- akta.pro primary industry
- eCOA/ePRO/eDiary & Patient-Facing Data Collection (HLACAOAB)
- akta.pro secondary industry
- Chronic Disease Management Pathways (e.g., diabetes, CHF, COPD) (HLACAGAG)
Keywords
Where Cardea Health is headquartered
LocationHeadquarters
- HQ city
- Mississauga
- HQ country
- Canada
- HQ region
- North America
Offices1 record
Markets served
Cardea Health business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations
Revenue model
- Clinical Trial Patient Recruitment Services: Cardea Health provides AI-powered patient pre-screening and recruitment services to pharmaceutical sponsors, helping reduce patient acquisition costs and accelerate trial timelines. Services include feasibility studies, cohort building, and protocol-ready patient lists for Phase II-IV clinical trials.
- Real-World Evidence (RWE) Programs: Generating real-world evidence from outpatient EMR data for sponsors including Novo Nordisk, Amgen, and Sanofi. Supports outcomes research, treatment pathway analyses, and care-gap measurement.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels5 records
Cardea Health product offering
Product offeringCore offering
Cardea Health operates the FLOW platform, an AI-powered cardiology-centric data infrastructure that structures longitudinal outpatient EMR data (both structured and unstructured) to support clinical trial patient pre-screening, real-world evidence (RWE) generation, and outpatient cardiology decision-making. The platform combines proprietary multi-agent AI, NLP, OCR, and a 250+ term cardiometabolic lexicon with a "Reviewer in the Loop" workflow to deliver protocol-ready patient cohorts and audit-ready outputs for pharmaceutical sponsors and clinical trial site networks.
Product overview
Cardea Health offers FLOW, a unified AI-powered cardiology data platform consisting of three integrated modules: ScreenFLOW for AI-powered patient pre-screening, SearchFLOW for data analysis and cohort identification, and WorkFLOW for consolidated patient data visualization. The platform structures longitudinal outpatient EMR data (both structured and unstructured) to power clinical trials, real-world evidence (RWE) generation, and implementation science initiatives across outpatient cardiology clinics in North America. The system leverages proprietary NLP and multi-agent AI to identify eligible patients in seconds, achieving 98.2% medication identification accuracy and 86% complex diagnosis accuracy, while reducing pre-screening costs by 50%.
Differentiator
Problem solved
Functional benefit
Products and services
- FLOW Platform Unified AI-powered cardiology-centric data platform that structures longitudinal outpatient EMR data to power clinical trial pre-screening, real-world evidence generation, and implementation science. Designed for pharmaceutical sponsors, clinical trial site networks, and outpatient cardiology clinics across North America.
Quantifiable outcome
- 50% reduction in patient acquisition costs for clinical trials
- +4 more outcomes
Companies that use Cardea Health
Customer profileNamed customers4 records
Segments3 records
Ideal customer profiles3 records
Cardea Health technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability6 records
Feature5 records
Cardea Health partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and supporting.
- Areti HealthcoreAI-powered partnership between Cardea Health and Areti Health to reshape clinical trials with smarter recruitment and faster randomization. The collaboration combines Cardea's AI patient pre-screening capabilities with Areti's technology to improve trial efficiency, cut costs, and boost diversity in clinical trials.
- SiteCentricsupportingEcosystem partner working with Cardea Health on clinical research site network collaboration. SiteCentric shares Cardea's belief that the future of clinical research depends on better data access and smarter workflows.
- QHR Technologies (Accuro)coreCardea Health became an Accuro Marketplace Vendor, offering cardiology solutions on QHR Technologies' Accuro EMR platform. This integration enables Cardea to reach outpatient clinics in Canada using the Accuro electronic medical records system.
- NovartiscoreInnovative partnership between Novartis, Cardea Health Inc., and Heart Health Institute for ASCVD management in Ontario. The collaboration focuses on cardiovascular disease management with data showing LDL decrease from baseline 2.5 to 1.2 after one visit. Data collected over 6 months with 1 nurse practitioner seeing average 9 ASCVD patients per day.
- Heart Health InstitutecoreHeart Health Institute operates 2 outpatient clinics with 11 cardiologists and is where Cardea Health founders Naveed Ahmad and Dr. Andrew Yadegari met. The partnership involves co-founding Cardea Health and ongoing collaboration on ASCVD management programs with Novartis.
Scale indicators8 records
Recent moves6 records
Expansion highlights6 records
Cardea Health competitors and assessment
Company assessmentBroad incumbents
- Syneos Health: Syneos Health is a biopharmaceutical solutions organization offering clinical development services and real-world evidence. Comparable customer overlap with pharma sponsors and similar RWE/trial workflows, but as a large diversified CRO rather than a focused AI tool.
- Flatiron Health: Flatiron Health (acquired by Roche) provides real-world evidence and EHR-derived clinical data primarily for oncology research and care delivery. Comparable as an RWE platform serving pharma sponsors, though oncology-focused and at much larger scale.
- ICON plc: ICON plc is a global CRO with significant clinical trial services and site network operations. Overlaps with Cardea's trial services and real-world evidence offerings but as a broad incumbent rather than an AI-native specialist.
- IQVIA: IQVIA is the largest CRO with E360 and other AI-driven clinical trial analytics, real-world evidence, and patient identification capabilities. Overlaps with Cardea's pharma sponsor GTM and RWE focus, but operates across all therapeutic areas and geographies.
- ConcertAI: ConcertAI provides AI-powered real-world evidence and clinical trial solutions for life sciences, particularly in oncology. Comparable in RWE generation and pharma customer base, but broader therapeutic scope and far larger scale than Cardea.
Direct peers
- Medable: Medable provides a clinical trial technology platform spanning eCOA, ePRO, telehealth, and decentralized trial workflows. Comparable as a clinical trial SaaS vendor serving pharma sponsors, though broader and more patient-centric than Cardea's EMR analytics focus.
- Castor: Castor offers an eClinical platform for decentralized and hybrid clinical trials with eCRF, ePRO, and eConsent modules. Comparable as a clinical trial data platform serving pharma and CROs, though more focused on data capture than patient identification.
- Deep 6 AI: Deep 6 AI builds AI-driven patient matching and cohort identification for clinical trials using structured and unstructured EMR data, directly comparable to Cardea's ScreenFLOW and SearchFLOW modules. Both target pharma sponsors and site networks to accelerate enrollment.
- Antidote (Trial Library): Antidote (now part of Trial Library) is a clinical trial recruitment and patient matching platform connecting sponsors with eligible patients. Overlapping pre-screening and recruitment workflow with Cardea's ScreenFLOW, although more patient-facing versus Cardea's EMR-first approach.
- Mendel: Mendel applies AI to clinical research and patient-trial matching across multiple therapeutic areas, with a comparable enterprise GTM to pharma sponsors. Its focus on automating chart review and eligibility mirrors Cardea's core value proposition.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
Cardea Health social profiles
Digital presenceCardea Health financial estimates
Financial estimateRevenue estimate
Valuation estimate
Cardea Health leadership team
Management profileNumber of profiles
Profiles3 records
Cardea Health funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Cardea Health M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Cardea Health
What does Cardea Health do?
Cardea Health operates the FLOW platform, an AI-powered cardiology-centric data infrastructure that structures longitudinal outpatient EMR data (both structured and unstructured) to support clinical trial patient pre-screening, real-world evidence (RWE) generation, and outpatient cardiology decision-making. The platform combines proprietary multi-agent AI, NLP, OCR, and a 250+ term cardiometabolic lexicon with a "Reviewer in the Loop" workflow to deliver protocol-ready patient cohorts and audit-ready outputs for pharmaceutical sponsors and clinical trial site networks.
Is Cardea Health a public or private company?
Cardea Health is a private company. It is classified as venture growth investor backed and is currently operating.
When was Cardea Health founded?
Cardea Health was founded in 2021. It employs 1 to 10 people.
Where is Cardea Health based?
Cardea Health is headquartered in Mississauga, Canada, in the North America region.
How does Cardea Health make money?
Two revenue lines are on record. Clinical Trial Patient Recruitment Services are the primary driver. The others are real-World Evidence (RWE) Programs.
Who are Cardea Health's main competitors?
Broad incumbents on record are Syneos Health, Flatiron Health, ICON plc, IQVIA and ConcertAI. Direct peers are Medable, Castor, Deep 6 AI, Antidote (Trial Library) and Mendel.
Does Cardea Health have an API?
No public API is recorded for Cardea Health.
What industry is Cardea Health in?
Cardea Health's product category is Clinical Trial Technology. Its primary akta.pro industry code is HLACAOAB, eCOA/ePRO/eDiary & Patient-Facing Data Collection, with a secondary code of HLACAGAG, Chronic Disease Management Pathways (e.g., diabetes, CHF, COPD). Its NAICS code is 518 and its SIC code is 7372.